Successful removal of Chlamydia pneumoniae from plateletpheresis products collected using automated leukoreduction

Wilmore Webley1, Elizabeth Stuart, Frances Cirino

  • 1Department of Microbiology, University of Massachusetts Amherst, Massachusetts 01003, USA. wilmore@microbio.umass.edu

Insights

Apheresis leukoreduction significantly reduces Chlamydia pneumoniae (Cp) in platelet products. This filtration process effectively removes the pathogen from white blood cells, enhancing blood product safety.

Area of Science:

  • Microbiology
  • Transfusion Medicine

Background:

  • Chlamydia pneumoniae (Cp) is an intracellular pathogen linked to various diseases, including pneumonia.
  • Previous research indicated leukoreduction might eliminate Cp from white blood cells.

Purpose of the Study:

  • To evaluate the efficacy of apheresis leukoreduction in reducing Cp carriage and infectivity in platelet products.
  • To assess the impact of leukoreduction on Cp presence in platelet collections from healthy donors.

Main Methods:

  • Analyzed pre-apheresis peripheral blood and post-leukoreduction platelet products from 115 donors.
  • Used direct smear inspection and tissue culture to detect Cp.
  • Assessed anti-Cp antibody seroreactivity via immunoassay.

Main Results:

  • 27% of donors had Cp in pre-apheresis blood by smear; 30% by culture.
  • 48% of donors showed elevated anti-Cp antibody titers.
  • Post-leukoreduction, only 1.7% of products were smear-positive and 0.009% culture-positive for Cp.

Conclusions:

  • Healthy donors can carry infectious Cp organisms in circulating white blood cells.
  • Standard apheresis leukoreduction effectively reduces or eliminates Cp in platelet products, improving blood safety.

Related Concept Videos